Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment ...

The FDA clearance unlocks multiple growth initiatives for HeartBeam. The company plans a limited commercial launch in Q1 2026 ...

Emerging fabrication techniques are re-writing the rulebook for on-chip components.

HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac ...

HeartBeam's FDA clearance for its cable-free at-home 12-lead ECG marks a pivotal step toward commercialization and broader cardiac-care adoption.

Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal. HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through ...

HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...

Engines have remained fairly true to form over the years without a lot of unusual changes, but a new Ferrari design could change everything.

H.C. Wainwright initiated coverage of HeartBeam (BEAT) with a Buy rating and $2.50 price target The firm says HeartBeam is a clinical-stage ...

Abstract: This article presents a multichroic Kinetic Inductance Bolometer (KIB) polarimeter that utilizes coplanar waveguide (CPW) diplexers. The CPW diplexers function as filters, providing two ...